HER-2 Positive Breast Cancer Latest Advances

Find the Latest Research About HER-2 Positive Breast Cancer

Last Updated: 02/24/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 670 publications

Integrative In-silico, Network Pharmacology, Pharmacogenomics and In-vitro Evaluation of Fulvestrant-Loaded Zinc Oxide Nanoparticles Targeting HER2 Positive Breast Cancer.

Integrative In-silico, Network Pharmacology, Pharmacogenomics and In-vitro Evaluation of Fulvestrant-Loaded Zinc Oxide Nanoparticles Targeting HER2 Positive Breast Cancer.

Journal: Pharmaceutical research
Published: November 29, 2025

Dually Decorated Palmitate-Containing Lipid Nanoparticles for the Targeted Delivery of siRNAs against HER2 and Hsp27 in HER2+ Breast Cancer.

Dually Decorated Palmitate-Containing Lipid Nanoparticles for the Targeted Delivery of siRNAs against HER2 and Hsp27 in HER2+ Breast Cancer.

Journal: Journal of medicinal chemistry
Published: November 24, 2025

T-DXd shows promise in neoadjuvant therapy for HER2+ breast cancer.

T-DXd shows promise in neoadjuvant therapy for HER2+ breast cancer.

Journal: Nature reviews. Clinical oncology
Published: November 10, 2025

The HER2MtGx Metagene Score as a Reliable Tool to Select HER2 Breast Cancer Patients for Neoadjuvant Targeted Therapy.

The HER2MtGx Metagene Score as a Reliable Tool to Select HER2 Breast Cancer Patients for Neoadjuvant Targeted Therapy.

Journal: International journal of molecular sciences
Published: October 21, 2025

Electrochemical aptasensing of HER2 breast cancer biomarker using a Ni nanofoam/Ag-Au ternary nanocomposite.

Electrochemical aptasensing of HER2 breast cancer biomarker using a Ni nanofoam/Ag-Au ternary nanocomposite.

Journal: Analytical and bioanalytical chemistry
Published: September 19, 2025

Development of a pH-responsive pegylated chitosan nanocarrier for targeted delivery of 17-AAG and synergistic therapy in HER2+ breast cancer.

Development of a pH-responsive pegylated chitosan nanocarrier for targeted delivery of 17-AAG and synergistic therapy in HER2+ breast cancer.

Journal: Scientific reports
Published: September 17, 2025

Synthesis and Evaluation of [177Lu]Lu-Labeled-NLS-Trastuzumab Conjugate for Targeting of HER2 Positive Metastatic Breast Cancer: Evaluating the Effect on Intracellular Localization.

Synthesis and Evaluation of [177Lu]Lu-Labeled-NLS-Trastuzumab Conjugate for Targeting of HER2 Positive Metastatic Breast Cancer: Evaluating the Effect on Intracellular Localization.

Journal: ACS medicinal chemistry letters
Published: August 01, 2025

Dose Adjusted Neoadjuvant Paclitaxel, Carboplatin, Trastuzumab and Pertuzumab in Women With HER2 Positive Early Breast Cancer.

Dose Adjusted Neoadjuvant Paclitaxel, Carboplatin, Trastuzumab and Pertuzumab in Women With HER2 Positive Early Breast Cancer.

Journal: Clinical breast cancer
Published: July 02, 2025

Review Article: Probiotics-Mediated Enhancement of Checkpoint Inhibitor Blockade for HER2+ Breast Cancer.

Review Article: Probiotics-Mediated Enhancement of Checkpoint Inhibitor Blockade for HER2+ Breast Cancer.

Journal: Critical reviews in oncogenesis
Published: June 25, 2025

Survival analysis of adjuvant endocrine therapy in HER2 positive early breast cancer patients with low ER positivity.

Survival analysis of adjuvant endocrine therapy in HER2 positive early breast cancer patients with low ER positivity.

Journal: Breast cancer research : BCR
Published: June 15, 2025

Anti-HER2/Neu Antibody Therapy Inhibits HER2+ Breast Cancer by Blocking Myeloid-Derived Suppressor Cell Activity.

Anti-HER2/Neu Antibody Therapy Inhibits HER2+ Breast Cancer by Blocking Myeloid-Derived Suppressor Cell Activity.

Journal: Oncology research and treatment
Published: June 11, 2025

Prescribing trends of adjuvant neratinib in hormone-positive HER2 positive breast cancer.

Prescribing trends of adjuvant neratinib in hormone-positive HER2 positive breast cancer.

Journal: Oncology
Published: June 09, 2025
Showing 1-12 of 670

Last Updated: 02/24/2026